ORGARAN 750 UNIT / 0.6 ML — DIN 02129043
DANAPAROID SODIUM : 750 UNIT / 0.6 ML · ASPEN PHARMACARE CANADA INC. · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ORGARAN?
ORGARAN 750 UNIT / 0.6 ML contains DANAPAROID SODIUM : 750 UNIT / 0.6 ML. It is listed in the Health Canada Drug Product Database under DIN 02129043, held by ASPEN PHARMACARE CANADA INC., supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 06-Nov-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ORGARAN used for?
Treatment of patients with an acute episode of Heparin-Induced Thrombocytopenia (HIT), and for prophylaxis in patients with a history of HIT.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Danaparoid cost around the world?
Danaparoid is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Luxembourg publishes a reimbursement. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Austria | KVP (Kassenverkaufspreis) | 1 | 1 | EUR███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
2 pack listings across 2 brand entries and 2 price bases, refreshed 05 Sep 2026. Ranges span every Danaparoid pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 750 UNIT / 0.6 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS ; INTRAVENOUS |
| Pack configuration (monograph) | 750 anti-Xa units/ampoule (1250 anti-Xa units/mL). |
| Storage | Not explicitly detailed in provided text (standard pharmaceutical storage usually applies, but not stated in snippet). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Danaparoid |
|---|---|
| ATC code | B01AB09 |
| AHFS class | 20:12.04.16 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02129043 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2129043 |
| Brand name | ORGARAN |
| Generic / active ingredient | DANAPAROID SODIUM : 750 UNIT / 0.6 ML |
| Market authorization holder | ASPEN PHARMACARE CANADA INC. |
| Health Canada schedule | Prescription |
| ATC code | B01AB09 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01AB |
| Current status | MARKETED |
| Status date | 06-Nov-2018 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administered SC or IV. Dosage must be individualized, especially in renal failure or for hemodialysis. Monitoring via anti-factor Xa levels is recommended as routine clotting assays are unsuitable.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Intramuscular route; history of thrombocytopenia/thrombosis with ORGARAN; severe untreated hypertension; diabetic/hemorrhagic retinopathy; acute hemorrhagic stroke; uncontrollable active bleeding.
Warnings and precautions
Risk of systemic bleeding; risk of spinal/epidural hematoma with anesthesia; contains sodium sulphite (allergic risk); not recommended for cardiopulmonary bypass or prosthetic heart valves.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC B01AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Enoxaparin | AXBERI · AXBERI HP · ELONOX · ELONOX HP · +9 more | 46 | 44 | Yes |
| Tinzaparin | INNOHEP · INNOHEP DISP.SYR.-11700 ANTI-XA IU/ML · LOGIPARIN LIQ SC 10000 FXAIU/ML | 13 | 11 | Yes |
| Heparin | CALCILEAN INJ 20000UNIT/0.8ML · CALCIPARINE INJ 20000IU/AMP · CALCIPARINE INJ 5000IU · HEPALEAN 10,000 USP · +17 more | 32 | 10 | Yes |
| Dalteparin | FRAGMIN · FRAGMIN INJ.-LIQ 2500 IU(ANTI-XA)/ML | 13 | 10 | Yes |
| Heparin, Combinations | HEPARIN SOD AND 0.9% SOD CHLORIDE INJ · HEPARIN SODIUM & 5% DEXTROSE INJECTION LIQ · HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ · HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ · +4 more | 8 | 4 | Yes |
| Antithrombin | ANTITHROMBIN III IMMUNO · ANTITHROMBIN III NF · THROMBATE III · THROMBATE III PWS IV 1000IU/VIAL · +1 more | 7 | 2 | Yes |
| Danaparoid | ORGARAN | 1 | 1 | Yes |
| Nadroparin | FRAXIPARINE · FRAXIPARINE FORTE | 8 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B01AF | Apixaban · Edoxaban · Rivaroxaban | 159 | 121 |
| B01AC | Abciximab · Acetylsalicylic Acid · Cangrelor · Clopidogrel · Combinations · +10 more | 158 | 66 |
| B01AA | Acenocoumarol · Warfarin | 62 | 16 |
| B01AE | Argatroban · Bivalirudin · Dabigatran Etexilate · Lepirudin | 18 | 11 |
| B01AX | Caplacizumab · Defibrotide · Fondaparinux | 10 | 5 |
| B01AD | Alteplase · Ancrod · Anistreplase · Drotrecogin Alfa · Reteplase · +3 more | 22 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ORGARAN called?
The same molecule, Danaparoid, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Orgaran Amp. | Latin | Austria |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.